Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for Cell & Gene Therapy Annual Meeting
May 04 2022 - 10:30AM
Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage
immuno-oncology company specializing in the development of
next-generation T cell-based immunotherapies for the treatment of
hematological malignancies and solid tumor indications, today
announced that the Company will present four posters on its
Multi-Tumor-Associated Antigen (MultiTAA)-specific T cell therapies
at the 2022 International Society for Cell & Gene Therapy
(ISCT) Annual Meeting, being held May 4-7, 2022, in San Francisco.
"We are excited to present data on our
state-of-the-art T cell therapy manufacturing process for our
MultiTAA-specific T cell product candidates at ISCT, including
improvements resulting in faster manufacturing time and increased
potency for our lead product candidate, MT-401, currently in a
Phase 2 study for the treatment of post-transplant AML,” said Peter
L. Hoang, President & CEO of Marker Therapeutics. “We look
forward to sharing additional details on our improved manufacturing
process, which we believe has the potential to enhance clinical
responses in patients. In addition, we will present more detail on
the clinical results from the six-patient safety lead-in stage of
our Phase 2 AML trial, previously reported in February 2022, which
demonstrate that MT-401 was well-tolerated, eliminated measurable
residual disease (MRD) in one MRD+ patient and induced epitope
spreading.”
The four posters will be presented on Thursday, May
5, from 5:45 p.m. – 7:15 p.m. PT.
- MT-401 (multi-tumor associated antigen-specific T
cells) utilized for treatment for MRD+ AML
patientsAbstract #: 515Presenter: Shukaib Arslan, MD, City
of Hope Comprehensive Cancer Center
- Long-term Characterization of T Cell Product
Interactions using in vitro 3D tumor models and the Go-Rex
PlatformAbstract #: 506Presenter: Eric A. Smith, PhD,
Marker Therapeutics
- Rapid and Simplified Process for Manufacturing
Multi-Tumor-Associated Antigen Specific T CellsAbstract #:
936Presenter: Anastasiya Smith, PhD, Marker Therapeutics
- Automating Closed System Purification of White Blood
Cells for T Cell Therapy ManufacturingAbstract #:
937Presenter: Anastasiya Smith, PhD, Marker Therapeutics
The posters will be available in the Publications
section of Marker’s website at https://www.markertherapeutics.com
at the beginning of the session.
About Marker Therapeutics,
Inc.Marker Therapeutics, Inc. is a clinical-stage
immuno-oncology company specializing in the development of
next-generation T cell-based immunotherapies for the treatment of
hematological malignancies and solid tumor indications. Marker’s
cell therapy technology is based on the selective expansion of
non-engineered, tumor-specific T cells that recognize tumor
associated antigens (i.e. tumor targets) and kill tumor cells
expressing those targets. This population of T cells is designed to
attack multiple tumor targets following infusion into patients and
to activate the patient’s immune system to produce broad spectrum
anti-tumor activity. Because Marker does not genetically engineer
its T cell therapies, we believe that our product candidates will
be easier and less expensive to manufacture, with reduced
toxicities, compared to current engineered CAR-T and TCR-based
approaches, and may provide patients with meaningful clinical
benefit. As a result, Marker believes its portfolio of T cell
therapies has a compelling product profile, as compared to current
gene-modified CAR-T and TCR-based therapies.
To receive future press releases via email, please
visit: https://www.markertherapeutics.com/email-alerts.
Forward-Looking StatementsThis
release contains forward-looking statements for purposes of the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Statements in this news release concerning the
Company’s expectations, plans, business outlook or future
performance, and any other statements concerning assumptions made
or expectations as to any future events, conditions, performance or
other matters, are “forward-looking statements.” Forward-looking
statements include statements regarding our intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things: our research, development and regulatory
activities and expectations relating to our non-engineered
multi-tumor antigen specific T cell therapies and our preclinical
pipeline; the effectiveness of these programs or the possible range
of application and potential curative effects and safety in the
treatment of diseases; the potential commercialization of our
current and future product candidates; our manufacturing processes
and the efficiencies and cost thereof; our ability to use our cGMP
manufacturing facility to support clinical and commercial demand;
and our ability to secure additional funding on favorable terms.
Forward-looking statements are by their nature subject to risks,
uncertainties and other factors which could cause actual results to
differ materially from those stated in such statements. Such risks,
uncertainties and factors include, but are not limited to the risks
set forth in the Company’s most recent Form 10-K, 10-Q and
other SEC filings which are available through EDGAR at www.sec.gov.
Such risks and uncertainties may be amplified by the COVID-19
pandemic and its impact on our business and the global economy. The
Company assumes no obligation to update our forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
Investors and Media Contacts
Marker Therapeutics:
Neda SafarzadehVice President/Head of Investor
Relations, PR & Marketing(713)
400-6451INVESTOR.RELATIONS@MARKERTHERAPEUTICS.COM
Solebury Trout:
MediaAmy
BonannoABONANNO@SOLEBURYTROUT.COM
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Apr 2023 to Apr 2024